Pharmaceutical drug development
Focused on making patient lives better
ImmuPharma PLC is a pharmaceutical development company focusing on developing novel medicines in specialist markets with serious unmet need. Lupuzor™ is the company’s most advanced drug in development and is a treatment for lupus, a life threatening autoimmune disease and has now completed dosing Lupus patients in its Phase III pivotal trial. This is only part of our story as our scientists and researchers are developing drugs to make life changing difference to peoples lives worldwide.
We continue to work with our long term partner Centre National de la Recherche Scientifique (CNRS), Europe’s largest fundamental research institution and ImmuPharma’s long standing collaboration partner.
Developing innovative drugs
ImmuPharma PLC is a pharmaceutical company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM), focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma has five drug candidates in development, two platform technologies and approximately 70 patents. The Company’s most advanced drug candidate recently received the approval from the US FDA to enter phase III with a Special Protocol Assessment and “Fast Track” designation. ImmuPharma is led by a commercially focused Board and management team with extensive experience.
ImmuPharma transforms care for people worldwide
Developing innovative drugs for serious medical conditions
Lupuzor™, is also known by its chemical name ‘Forigerimod’ or P140. ImmuPharma has the potential of expanding the P140 peptide platform into other auto immune conditions such as: Rheumatoid Arthritis, Crohn’s Disease, and Asthma. Very few AIM-listed drug development companies have late-stage clinical assets of similar calibre.
Oncology & Ophthalmology
ImmuPharma’s second most advanced pipeline program, IPP-204106, is a potential treatment for various cancers and acts by modulating angiogenesis (formation of new blood vessels) and proliferation (rapid reproduction). We are also investigating its use in age-related macular degeneration, diabetic retinopathy and other ophthalmological indications.
Metabolism and diabetes
ImmuPharma’s subsidiary ‘Ureka’ has initiated the development of a novel and innovative peptide technology platform through the collaboration with CNRS, gaining access to pioneering research centred on novel peptide drugs at the University of Bordeaux and the Institut Européen de Chimie et Biologie (IECB). The first therapeutic area being targeted is diabetes.